CA3000405A1 - Methods for subtyping diffuse large b-cell lymphoma (dlbcl) - Google Patents
Methods for subtyping diffuse large b-cell lymphoma (dlbcl) Download PDFInfo
- Publication number
- CA3000405A1 CA3000405A1 CA3000405A CA3000405A CA3000405A1 CA 3000405 A1 CA3000405 A1 CA 3000405A1 CA 3000405 A CA3000405 A CA 3000405A CA 3000405 A CA3000405 A CA 3000405A CA 3000405 A1 CA3000405 A1 CA 3000405A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- sample
- ptprc
- pim1
- rel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562234491P | 2015-09-29 | 2015-09-29 | |
| US62/234,491 | 2015-09-29 | ||
| PCT/US2016/054501 WO2017059108A1 (en) | 2015-09-29 | 2016-09-29 | Methods for subtyping diffuse b-cell lymphoma (dlbcl) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3000405A1 true CA3000405A1 (en) | 2017-04-06 |
Family
ID=57138148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3000405A Pending CA3000405A1 (en) | 2015-09-29 | 2016-09-29 | Methods for subtyping diffuse large b-cell lymphoma (dlbcl) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11384399B2 (https=) |
| EP (1) | EP3356554B1 (https=) |
| JP (1) | JP6836586B2 (https=) |
| CN (1) | CN108368554B (https=) |
| AU (1) | AU2016331058B2 (https=) |
| BR (1) | BR112018006393A2 (https=) |
| CA (1) | CA3000405A1 (https=) |
| ES (1) | ES2765709T3 (https=) |
| WO (1) | WO2017059108A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11696250B2 (en) * | 2016-11-09 | 2023-07-04 | Intel Corporation | UE and devices for detach handling |
| EP3638814B8 (en) | 2017-06-14 | 2023-06-21 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Method for determining lymphoma type |
| WO2019036632A1 (en) * | 2017-08-18 | 2019-02-21 | Health Research, Inc. | COMPOSITIONS AND METHODS FOR DETECTION OF CD30 MRM ISOFORMS FOR USE IN DRUG SELECTION |
| JP7357921B2 (ja) * | 2017-09-29 | 2023-10-10 | 国立大学法人九州大学 | びまん性大細胞型b細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット |
| CA3128973A1 (en) | 2019-03-04 | 2020-09-10 | Bhaskar Bhattacharyya | Data compression and communication using machine learning |
| AU2020245086B2 (en) * | 2019-03-28 | 2026-01-08 | Centre Henri Becquerel | Classification of B-Cell non-Hodgkin Lymphomas |
| CN111621565B (zh) * | 2020-05-07 | 2023-12-15 | 杭州可帮基因科技有限公司 | 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置 |
| CN114469949A (zh) * | 2020-10-27 | 2022-05-13 | 正大天晴药业集团股份有限公司 | 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物 |
| CN117987359B (zh) * | 2024-02-18 | 2024-08-30 | 中源协和生物细胞存储服务(天津)有限公司 | 用于从生物材料中分离细胞外囊泡的方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE69132531T2 (de) | 1990-12-06 | 2001-09-13 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Verbindungen und ihre Verwendung in einer binären Synthesestrategie |
| US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| WO1995030774A1 (en) | 1994-05-05 | 1995-11-16 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
| US5585069A (en) | 1994-11-10 | 1996-12-17 | David Sarnoff Research Center, Inc. | Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5866330A (en) | 1995-09-12 | 1999-02-02 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| US5736330A (en) | 1995-10-11 | 1998-04-07 | Luminex Corporation | Method and compositions for flow cytometric determination of DNA sequences |
| US6449562B1 (en) | 1996-10-10 | 2002-09-10 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
| GB9624586D0 (en) | 1996-11-27 | 1997-01-15 | British Nuclear Fuels Plc | Improvements in and relating to coils |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6232066B1 (en) | 1997-12-19 | 2001-05-15 | Neogen, Inc. | High throughput assay system |
| WO2000037684A1 (en) | 1998-12-22 | 2000-06-29 | Kris Richard M | High throughput assay system using mass spectrometry |
| US6238869B1 (en) | 1997-12-19 | 2001-05-29 | High Throughput Genomics, Inc. | High throughput assay system |
| US6458533B1 (en) | 1997-12-19 | 2002-10-01 | High Throughput Genomics, Inc. | High throughput assay system for monitoring ESTs |
| US20030096232A1 (en) | 1997-12-19 | 2003-05-22 | Kris Richard M. | High throughput assay system |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| US20110152115A1 (en) * | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| DE102005030336A1 (de) | 2005-06-29 | 2007-01-04 | Peri Gmbh | Schienengeführtes Klettersystem |
| EP1963531B1 (en) | 2005-12-23 | 2011-09-21 | Nanostring Technologies, Inc. | Nanoreporters and methods of manufacturing and use thereof |
| US20080268451A1 (en) | 2007-03-30 | 2008-10-30 | Bruce Seligmann | Measurement of an insoluble analyte in a sample |
| UA104868C2 (uk) | 2008-08-15 | 2014-03-25 | Меррімак Фармасьютікалз, Інк. | Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції |
| US8986958B2 (en) * | 2009-03-30 | 2015-03-24 | Life Technologies Corporation | Methods for generating target specific probes for solution based capture |
| TWI509247B (zh) | 2010-03-12 | 2015-11-21 | 西建公司 | 利用雷那度胺(lenalidomide)治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記 |
| CN103649335B (zh) * | 2011-05-04 | 2015-11-25 | Htg分子诊断有限公司 | 定量核酸酶保护测定(qnpa)和测序(qnps)的改进 |
| US10607717B2 (en) * | 2013-11-06 | 2020-03-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for subtyping lymphoma types by means of expression profiling |
-
2016
- 2016-09-29 CN CN201680069786.XA patent/CN108368554B/zh active Active
- 2016-09-29 US US15/756,641 patent/US11384399B2/en active Active
- 2016-09-29 AU AU2016331058A patent/AU2016331058B2/en not_active Ceased
- 2016-09-29 EP EP16782152.9A patent/EP3356554B1/en active Active
- 2016-09-29 ES ES16782152T patent/ES2765709T3/es active Active
- 2016-09-29 BR BR112018006393-2A patent/BR112018006393A2/pt not_active Application Discontinuation
- 2016-09-29 CA CA3000405A patent/CA3000405A1/en active Pending
- 2016-09-29 JP JP2018515957A patent/JP6836586B2/ja active Active
- 2016-09-29 WO PCT/US2016/054501 patent/WO2017059108A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016331058B2 (en) | 2022-04-07 |
| JP6836586B2 (ja) | 2021-03-03 |
| CN108368554A (zh) | 2018-08-03 |
| ES2765709T3 (es) | 2020-06-10 |
| EP3356554A1 (en) | 2018-08-08 |
| EP3356554B1 (en) | 2019-10-30 |
| US20180340231A1 (en) | 2018-11-29 |
| CN108368554B (zh) | 2022-09-09 |
| JP2018536387A (ja) | 2018-12-13 |
| BR112018006393A2 (pt) | 2018-10-09 |
| US11384399B2 (en) | 2022-07-12 |
| AU2016331058A1 (en) | 2018-04-26 |
| WO2017059108A1 (en) | 2017-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016331058B2 (en) | Methods for subtyping diffuse large b-cell lymphoma (dlbcl) | |
| EP3737774B1 (en) | Method for analyzing nucleic acid | |
| EP2864500B1 (en) | Molecular malignancy in melanocytic lesions | |
| JP2021508460A (ja) | Crisprエフェクター系に基づくマルチプレックス診断 | |
| Coudry et al. | Successful application of microarray technology to microdissected formalin-fixed, paraffin-embedded tissue | |
| KR20190104030A (ko) | Crispr 이펙터 시스템 기반 진단 | |
| US20130178372A1 (en) | Methods And Computer Systems For Identifying Target-Specific Sequences For Use In Nanoreporters | |
| JP2018524993A (ja) | 染色体異常を検出するための核酸及び方法 | |
| AU2016297510A1 (en) | Methods of amplifying nucleic acid sequences | |
| WO2014149629A1 (en) | Subtyping lung cancers | |
| CA2859663A1 (en) | Identification of multigene biomarkers | |
| EP4172357B1 (en) | Methods and compositions for analyzing nucleic acid | |
| EP3358020B1 (en) | Diagnostic test system for specific, sensitive and reproducible detection of circulating nucleic acids in whole blood | |
| US20220220546A1 (en) | Sherlock assays for tick-borne diseases | |
| JP2023109998A (ja) | マイクロサテライト不安定性の検出 | |
| WO2010021696A1 (en) | Methods and compositions for determining a graft tolerant phenotype in a subject | |
| Joseph et al. | Molecular Techniques/Molecular Diagnostics for Surgical Pathologists: An Overview | |
| Yang et al. | The Technologies: Comparisons on Efficiency, Reliability, and Costs | |
| EP4584373A1 (en) | Methods and compositions for analyzing nucleic acid | |
| WO2023250397A1 (en) | Methods for the molecular subtyping of tumors from archival tissue | |
| Dunbar et al. | Bead array technologies for genetic disease screening and microbial detection | |
| HK1199070A1 (en) | Methods of amplifying whole genome of a single cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210922 |
|
| C11 | Application revival requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED Effective date: 20240828 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20240828 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240923 |
|
| C11 | Application revival requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED Effective date: 20241031 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251211 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260224 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260311 |
|
| C13 | Application revived following an application revival request |
Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: FINAL FEE PAID AND APPLICATION REINSTATED Effective date: 20260330 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260330 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260330 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260330 |